Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants

Brazil currently has a 10-valent pneumococcal conjugate vaccine (PCV10) pediatric national immunization program (NIP). However, in recent years, there has been significant progressive increases in pneumococcal disease attributed to serotypes 3, 6A, and 19A, which are covered by the 13-valent PCV (PC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hum Vaccin Immunother
Main Authors: Perdrizet, Johnna, Santana, Carlos Felipe S., Senna, Thais, Alexandre, Rodrigo Fernandes, Sini de Almeida, Rodrigo, Spinardi, Julia, Wasserman, Matt
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2020
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018448/
https://ncbi.nlm.nih.gov/pubmed/32966176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2020.1809266
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados